NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm today said that it and preferred provider organization Stratose have entered into a contract to cover the PCDx test.
Stratose, based in Atlanta, has more than 850,000 direct and affiliate contracts with providers nationwide. Stratose's members will now have access to the PCDx next-generation sequencing-based test, which identifies the underlying genomic and proteomic mutations in a patient's tumor DNA, RNA, and proteins.